Patents Assigned to GENEURO SA
-
Patent number: 10981977Abstract: The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or is therapy.Type: GrantFiled: June 17, 2020Date of Patent: April 20, 2021Assignees: GENEURO SA, THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Hervé Perron, Julie Medina, Avindra Nath, Joseph Perry Steiner, Wenxue Li, Myoung-Hwa Lee
-
Patent number: 10894820Abstract: The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.Type: GrantFiled: March 22, 2019Date of Patent: January 19, 2021Assignee: GENEURO SAInventors: Herve Perron, Francois Curtin, Alois Lang, Raphael Faucard, Julie Medina, Alexandra Madeira, Nadege Gehin
-
Patent number: 10723787Abstract: The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.Type: GrantFiled: January 19, 2018Date of Patent: July 28, 2020Assignees: GENEURO SA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Hervé Perron, Julie Medina, Avindra Nath, Joseph Perry Steiner, Wenxue Li, Myound-Hwa Lee
-
Patent number: 10059758Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.Type: GrantFiled: October 26, 2017Date of Patent: August 28, 2018Assignee: GENEURO SAInventors: Corinne Bernard, Alois Bernhardt Lang, Herve Perron, Jean-Baptiste Bertrand
-
Publication number: 20180057569Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.Type: ApplicationFiled: October 26, 2017Publication date: March 1, 2018Applicant: GENEURO SAInventors: Corinne BERNARD, Alois Bernhardt LANG, Herve PERRON, Jean-Baptiste BERTRAND
-
Patent number: 9815888Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.Type: GrantFiled: December 2, 2016Date of Patent: November 14, 2017Assignee: GENEURO SAInventors: Corinne Bernard, Alois Bernhardt Lang, Herve Perron, Jean-Baptiste Bertrand
-
Publication number: 20170107274Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.Type: ApplicationFiled: December 2, 2016Publication date: April 20, 2017Applicant: GENEURO SAInventors: Corinne BERNARD, Alois Bernhardt LANG, Herve PERRON, Jean-Baptiste BERTRAND
-
Patent number: 9550824Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.Type: GrantFiled: March 21, 2014Date of Patent: January 24, 2017Assignee: GENEURO SAInventors: Corinne Bernard, Alois Bernhardt Lang, Herve Perron, Jean-Baptiste Bertrand
-
Publication number: 20140220026Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.Type: ApplicationFiled: March 21, 2014Publication date: August 7, 2014Applicant: GENEURO SAInventors: Corinne BERNARD, Alois Bernhardt LANG, Herve PERRON, Jean-Baptiste BERTRAND
-
Patent number: 8715656Abstract: The present invention deals with a ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1(SEQ ID No. 1), from 0 to 2 in CDR2(SEQ ID No. 2), from 0 to 2 in CDR3(SEQ ID No. 3), from 0 to 1 in CDR4(SEQ ID No. 4), from 0 to 4 in CDR5(SEQ ID No. 5), from 0 to 2 in CDR6(SEQ ID No. 6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.Type: GrantFiled: July 8, 2009Date of Patent: May 6, 2014Assignee: Geneuro SAInventors: Corinne Bernard, Alois Bernhardt Lang, Herve Perron, Jean-Baptiste Bertrand
-
Publication number: 20110243962Abstract: The present invention deals with a ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1(SEQ ID No. 1), from 0 to 2 in CDR2(SEQ ID No. 2), from 0 to 2 in CDR3(SEQ ID No. 3), from 0 to 1 in CDR4(SEQ ID No. 4), from 0 to 4 in CDR5(SEQ ID No. 5), from 0 to 2 in CDR6(SEQ ID No. 6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.Type: ApplicationFiled: July 8, 2009Publication date: October 6, 2011Applicant: GENEURO SAInventors: Corinne Bernard, Alois Bernhardt Lang, Herve Perron, Jean-Baptiste Bertrand
-
Publication number: 20100074894Abstract: A pharmaceutical composition that contains, as an active ingredient, at least one antibody directed against the HERV-W envelope protein, except for any antibody specifically directed against the binding site between said env protein and the hASCT1 or hASCT2 receptor.Type: ApplicationFiled: February 11, 2008Publication date: March 25, 2010Applicant: GENEURO SAInventor: Herve Perron